Review decision - January 2016
Review of NICE Technology Appraisal Guidance No. 260; Botulinum toxin type A for the prophylaxis of headaches associated with chronic migraine
Decision to move the guidance to the static list – January 2016
The Institute was proposing that the guidance should move to the ‘static list’.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, TA260 will move to the ‘static list’. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: 11 January 2016